Company overview
Basic information
Company name
Beribio miesto pakraštys, MB
Company code
307026246
VAT code
LT100017754312
Registered address
Klaipėda, Debreceno g. 13-36B, LT-94174
Registration date
2024-11-14
Company age: 1 y. 11 mo.
Contact information
Edit data
Phone
Presented as an image – cannot be copied
Email
Presented as an image – cannot be copied
Website
None
Company manager
For registered members only
Log in
Indicators
Risk factors
Activity
Legal form
Small partnership
NACE activity
Installation of electrical wiring and fittings in buildings
Ownership form
Private without foreign capital
MB Beribio miesto pakraštys
Company code: 307026246
Address: Klaipėda, Debreceno g. 13-36B, LT-94174
VAT code: LT100017754312
Description
This description was generated by artificial intelligence.
Beribio miesto pakraštys, MB (company code 307026246) is an operational private small partnership registered in 2024. It belongs to the sector of national private non-financial companies and is described as privately owned, with Lithuanian natural and legal persons holding more than 50% of the authorised capital and no foreign investor capital. Governance is listed as CEO only. The company is based in Klaipeda, at Debreceno g. 13-36B, Klaipedos m. sav., Klaipedos apskr. Its registered activity is EVRK F.43.21.10, installation of electrical wiring and fittings in buildings and constructions. Financially, the company reported revenue of €35.8K in 2025, compared with €3.5K in its 47-day 2024 reporting period. Net profit remained modest at €85 in 2025, after €84 in 2024, and the profit margin was 0.2% in 2025. At the end of 2025, equity stood at €220, liabilities at €2.4K, and total assets at €2.6K. Latest staff-year information is available so far in 2026, but no average employee or wage figures are provided in the available data.
Download a detailed company report
Make confident decisions with all the information about Beribio miesto pakraštys, MB. In one document, you will find full financial data, risk and potential assessment, and key Scoris insights.